- Home
- KROS vs IGR Comparison
KROS vs IGR Comparison
Compare KROS & IGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KROS | IGR |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 584.9M | 645.2M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | KROS | IGR |
|---|---|---|
| Price | $11.49 | $4.72 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $21.86 | N/A |
| AVG Volume (30 Days) | 335.5K | ★ 603.3K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.93% |
| EPS Growth | ★ 146.00 | N/A |
| EPS | ★ 2.30 | N/A |
| Revenue | ★ $243,864,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,751.79 | N/A |
| P/E Ratio | $5.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.42 | $4.15 |
| 52 Week High | $22.55 | $5.37 |
Technical Indicators
Market Signals| Indicator | KROS | IGR |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 54.71 |
| Support Level | $10.56 | $4.65 |
| Resistance Level | $12.65 | $4.89 |
| Average True Range (ATR) | 0.42 | 0.07 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 37.50 | 61.54 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About IGR CBRE Global Real Estate Income Fund of Beneficial Interest
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.